Blood test may predict which triple-negative breast cancers will return
NCT ID NCT06418126
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether measuring certain inflammatory proteins (cytokines) in the blood during radiotherapy can help predict which triple-negative breast cancer patients are likely to have their cancer come back. Researchers will take blood samples from 15 women before and during radiotherapy and track their health for up to 5 years. The goal is to find a simple way to identify high-risk patients who might need extra treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a blood test that identifies which TNBC patients are at high risk of recurrence after radiotherapy.
What could go wrong
This is a very small, early-stage study with only 15 participants. It is observational and does not test a new treatment, so results may not lead to a usable test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut de cancérologie Strasbourg europe
Strasbourg, 67033, France